Back to Browse Journals » Transplant Research and Risk Management » Volume 1 » Default

Managing hepatitis C in liver transplant patients with recurrent infection

Authors Tim Zimmermann, Gerd Otto, Marcus Schuchmann

Published Date September 2009 Volume 2009:1(Default) Pages 1—14

DOI http://dx.doi.org/10.2147/TRRM.S4615

Published 13 September 2009

Tim Zimmermann1, Gerd Otto2, Marcus Schuchmann1

1Department of Internal Medicine, 2Transplantation Surgery, University of Mainz, Germany

Abstract: Hepatitis C virus (HCV) reinfection after liver transplantation (LT) and recurrent hepatitis C often lead to recurrent cirrhosis (RC). RC is one of the most frequent complications resulting in organ failure and early death after LT in HCV-positive patients with reported 5-year rates from 20% to 40%. As HCV-cirrhosis is one of the leading indications for LT, the therapeutic management is a central issue. To date, the best available therapy is a combination of pegylated interferon + ribavirin in patients with established recurrent hepatitis C proven by liver biopsy. Although increasing experience in using interferon therapy after LT has suggested better response rates, treatment is limited by a poor tolerability and high rates of severe side effects, necessitating lower doses or withdrawal of therapy. The extent to which dose reductions and the concomitant administration of growth factors affect virological response or prevent complications is still to be determined. Prospective clinical trials are mandatory to identify the best time point and schedule of antiviral treatment in transplant patients. Currently, therapeutic options need to be discussed for each individual patient. Therefore therapy should be carried out only in transplant centers with experience in managing hepatitis C after LT.

Keywords: hepatitis C, liver transplantation, recurrent infection, treatment

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Infused autograft lymphocyte to monocyte ratio predicts survival in classical Hodgkin lymphoma

Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Hogan WJ, Markovic SN

Journal of Blood Medicine 2015, 6:45-53

Published Date: 2 February 2015

Managing comorbidities in COPD

Hillas G, Perlikos F, Tsiligianni I, Tzanakis N

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:95-109

Published Date: 7 January 2015

Influence of immune activation and inflammatory response on cardiovascular risk associated with the human immunodeficiency virus

Beltrán LM, Rubio-Navarro A, Amaro-Villalobos JM, Egido J, García-Puig J, Moreno JA

Vascular Health and Risk Management 2015, 11:35-48

Published Date: 6 January 2015

Isolated posterior uveal effusion: expanding the spectrum of the uveal effusion syndrome

Pautler SE, Browning DJ

Clinical Ophthalmology 2015, 9:43-49

Published Date: 30 December 2014

Lung transplantation for chronic obstructive pulmonary disease

Liou TG, Raman SM, Cahill BC

Transplant Research and Risk Management 2013, 5:1-20

Published Date: 4 July 2013

Lebrikizumab in the personalized management of asthma

Thomson NC, Patel M, Smith AD

Biologics: Targets and Therapy 2012, 6:329-335

Published Date: 14 September 2012

Facial transplantation: a review of ethics, progress, and future targets

Edwards JA, Mathes DW

Transplant Research and Risk Management 2011, 3:113-125

Published Date: 5 September 2011

Low antigenicity of hematopoietic progenitor cells derived from human ES cells

Eun-Mi Kim, Nicholas Zavazava

Transplant Research and Risk Management 2010, 2:15-22

Published Date: 3 February 2010